-
Je něco špatně v tomto záznamu ?
Identification, characterization, and engineering of glycosylation in thrombolytics
M. Toul, V. Slonkova, J. Mican, A. Urminsky, M. Tomkova, E. Sedlak, D. Bednar, J. Damborsky, L. Hernychova, Z. Prokop
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem
- MeSH
- fibrinolytika terapeutické užití MeSH
- glykosylace MeSH
- infarkt myokardu * farmakoterapie MeSH
- lidé MeSH
- tenektepláza MeSH
- tkáňový aktivátor plazminogenu * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Cardiovascular diseases, such as myocardial infarction, ischemic stroke, and pulmonary embolism, are the most common causes of disability and death worldwide. Blood clot hydrolysis by thrombolytic enzymes and thrombectomy are key clinical interventions. The most widely used thrombolytic enzyme is alteplase, which has been used in clinical practice since 1986. Another clinically used thrombolytic protein is tenecteplase, which has modified epitopes and engineered glycosylation sites, suggesting that carbohydrate modification in thrombolytic enzymes is a viable strategy for their improvement. This comprehensive review summarizes current knowledge on computational and experimental identification of glycosylation sites and glycan identity, together with methods used for their reengineering. Practical examples from previous studies focus on modification of glycosylations in thrombolytics, e.g., alteplase, tenecteplase, reteplase, urokinase, saruplase, and desmoteplase. Collected clinical data on these glycoproteins demonstrate the great potential of this engineering strategy. Outstanding combinatorics originating from multiple glycosylation sites and the vast variety of covalently attached glycan species can be addressed by directed evolution or rational design. Directed evolution pipelines would benefit from more efficient cell-free expression and high-throughput screening assays, while rational design must employ structure prediction by machine learning and in silico characterization by supercomputing. Perspectives on challenges and opportunities for improvement of thrombolytic enzymes by engineering and evolution of protein glycosylation are provided.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010800
- 003
- CZ-PrNML
- 005
- 20230801132630.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biotechadv.2023.108174 $2 doi
- 035 __
- $a (PubMed)37182613
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Toul, Martin $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Kamenice 5/C13, 625 00 Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 656 91 Brno, Czech Republic
- 245 10
- $a Identification, characterization, and engineering of glycosylation in thrombolytics / $c M. Toul, V. Slonkova, J. Mican, A. Urminsky, M. Tomkova, E. Sedlak, D. Bednar, J. Damborsky, L. Hernychova, Z. Prokop
- 520 9_
- $a Cardiovascular diseases, such as myocardial infarction, ischemic stroke, and pulmonary embolism, are the most common causes of disability and death worldwide. Blood clot hydrolysis by thrombolytic enzymes and thrombectomy are key clinical interventions. The most widely used thrombolytic enzyme is alteplase, which has been used in clinical practice since 1986. Another clinically used thrombolytic protein is tenecteplase, which has modified epitopes and engineered glycosylation sites, suggesting that carbohydrate modification in thrombolytic enzymes is a viable strategy for their improvement. This comprehensive review summarizes current knowledge on computational and experimental identification of glycosylation sites and glycan identity, together with methods used for their reengineering. Practical examples from previous studies focus on modification of glycosylations in thrombolytics, e.g., alteplase, tenecteplase, reteplase, urokinase, saruplase, and desmoteplase. Collected clinical data on these glycoproteins demonstrate the great potential of this engineering strategy. Outstanding combinatorics originating from multiple glycosylation sites and the vast variety of covalently attached glycan species can be addressed by directed evolution or rational design. Directed evolution pipelines would benefit from more efficient cell-free expression and high-throughput screening assays, while rational design must employ structure prediction by machine learning and in silico characterization by supercomputing. Perspectives on challenges and opportunities for improvement of thrombolytic enzymes by engineering and evolution of protein glycosylation are provided.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a tkáňový aktivátor plazminogenu $7 D010959
- 650 _2
- $a tenektepláza $7 D000077785
- 650 _2
- $a glykosylace $7 D006031
- 650 _2
- $a fibrinolytika $x terapeutické užití $7 D005343
- 650 12
- $a infarkt myokardu $x farmakoterapie $7 D009203
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Slonkova, Veronika $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Kamenice 5/C13, 625 00 Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 656 91 Brno, Czech Republic
- 700 1_
- $a Mican, Jan $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Kamenice 5/C13, 625 00 Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 656 91 Brno, Czech Republic
- 700 1_
- $a Urminsky, Adam $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
- 700 1_
- $a Tomkova, Maria $u Center for Interdisciplinary Biosciences, P. J. Safarik University in Kosice, Jesenna 5, 04154 Kosice, Slovakia
- 700 1_
- $a Sedlak, Erik $u Center for Interdisciplinary Biosciences, P. J. Safarik University in Kosice, Jesenna 5, 04154 Kosice, Slovakia
- 700 1_
- $a Bednar, David $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Kamenice 5/C13, 625 00 Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 656 91 Brno, Czech Republic
- 700 1_
- $a Damborsky, Jiri $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Kamenice 5/C13, 625 00 Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 656 91 Brno, Czech Republic
- 700 1_
- $a Hernychova, Lenka $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic. Electronic address: lenka.hernychova@mou.cz
- 700 1_
- $a Prokop, Zbynek $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Kamenice 5/C13, 625 00 Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 656 91 Brno, Czech Republic. Electronic address: zbynek@chemi.muni.cz
- 773 0_
- $w MED00000793 $t Biotechnology advances $x 1873-1899 $g Roč. 66, č. - (2023), s. 108174
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37182613 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132627 $b ABA008
- 999 __
- $a ok $b bmc $g 1963306 $s 1197065
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 66 $c - $d 108174 $e 20230512 $i 1873-1899 $m Biotechnology advances $n Biotechnol Adv $x MED00000793
- LZP __
- $a Pubmed-20230718